✨
AI Summary
- Orgenesis CEO Vered Caplan discusses manufacturing cell and gene therapies at the point of care.
- The model involves adapting therapies for closed-system manufacturing within hospitals and healthcare providers.
- This approach aims to decentralize CGT development and delivery, moving away from traditional biotech models.
Guests on This Episode
VC
Vered Caplan
1 podcast appearance